Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168464 · ClinicalTrials.gov registry record · Phase 1
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03168464 is a Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 15 participants.
The verdict
NCT03168464, a Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
NSCLC patients with metastatic disease who have failed at least one prior treatment and have a minimum of two metastatic lesions (at least one measurable), are eligible if they have an ECOG Performance Status of 0-1. Patients will receive on Day 1, ipilimumab (every 6 weeks) concurrently with radiation (6Gy x 5 fractions). Nivolumab (every 2 weeks) will be given in addition to ipilimumab on day 22.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- RADIATION Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2022-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03168464
The ClinicalTrials.gov registry entry for NCT03168464 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03168464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03168464 about?
NCT03168464 is a clinical study titled "Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)". NSCLC patients with metastatic disease who have failed at least one prior treatment and have a minimum of two metastatic lesions (at least one measurable), are eligible if they have an ECOG Performance Status of 0-1. Patients will receive on Day 1, ipilimumab (every 6 weeks) concurrently with radiat...
What is the current status of trial NCT03168464?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-10-09. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT03168464?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT03168464?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.